Key result
LV-GLS identifies subclinical dysfunction and sharpens risk stratification in hypertrophic cardiomyopathy.
Why the study?
Does integrating left ventricular global longitudinal strain (LV-GLS) with other imaging biomarkers improve detection of subclinical LV dysfunction and risk stratification in patients with hypertrophic cardiomyopathy?
Does integrating left ventricular global longitudinal strain (LV-GLS) with other imaging biomarkers improve detection of subclinical LV dysfunction and risk stratification in patients with hypertrophic cardiomyopathy?
Integrating LV global longitudinal strain with other imaging biomarkers such as late gadolinium enhancement and left atrial reservoir strain may improve subclinical LV dysfunction detection and risk prediction in hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May refine hypertrophic cardiomyopathy risk stratification; leaves open prospective validation of integrated imaging biomarkers.
Hypertrophic cardiomyopathy (HCM) is an inherited disease characterized by increased myocardial thickness without cardiac, systemic, or metabolic causes to explain the observed left ventricular (LV) hypertrophy. Importantly, LV systolic dysfunction influences symptoms, heart failure, and the risk of SCD in HCM. LV global longitudinal strain (LV-GLS) is a sensitive marker for detecting subclinical LV dysfunction and improving risk stratification. Integrating LV-GLS with other imaging biomarkers, such as late gadolinium enhancement and left atrial reservoir strain, may improve risk prediction. Future research should focus on refining LV-GLS cutoffs and exploring its utility for personalized risk assessment in HCM.
No takes yet. Share an insight, caveat, or question.
Kwak et al. (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Left ventricular global longitudinal strain (LV-GLS) was evaluated on Subclinical LV systolic dysfunction and risk stratification (symptoms, heart failure, sudden cardiac death). LV global longitudinal strain (LV-GLS) is a sensitive marker for detecting subclinical LV dysfunction and improving risk stratification in hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: